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EDITORIAL
Treg Cells to the Rescue
David A. Fox
In this issue of Arthritis & Rheumatism, Kong and
colleagues report that collagen-induced arthritis (CIA),
a mouse model of rheumatoid arthritis (RA), can be
effectively treated by systemic injection of Treg cells (1).
These results raise several questions: Are there defects
in Treg cell numbers or function in RA? How should
Treg cells be collected, generated, or expanded for
use in the treatment of immune-mediated diseases?
What are the risks of using Treg cells in human rheu-
matic diseases? Would such an approach be practical?
And can we correct Treg cell dysfunction in vivo using
other approaches that do not require direct infusion of
these cells?
Immune responses are regulated at multiple levels
The adaptive immune response is mediated by
T and B lymphocytes that possess clonal specificity for
peptide or nonpeptide antigens, both foreign and self.
Negative selection (death) of highly autoreactive T cells
occurs during the development and maturation of these
cells in the thymus, but the process is incomplete, and
autoreactivity persists in the repertoire of T cells that are
found in normal lymphoid organs and in the circulation.
A system of checks and balances is needed not only to
limit the potential for this persistent autoreactivity to
evolve into autoimmune disease, but also to calibrate the
degree and duration of immune responses to foreign
antigens, so that successful host defense does not lead to
excessive chronic inflammation. Table 1 lists some of the
cells of the immune system that have roles in regulating
T lymphocyte responses. Thus, Treg cells do not func-
tion in isolation, but instead in the context of (and often
in concert with) other cells, such as Breg cells (2),
dendritic cells, natural killer T cells, CD8 T cells
(known long ago as suppressor T cells), and others.
Characteristics of Treg cells
Although immunoregulatory roles of CD4
T cells had been described in the 1980s, the recognition
in 1995 of CD25 (a subunit of the interleukin-2 receptor
[IL-2R]) as a surface marker of such cells allowed Treg
cells to be more specifically identified and studied (for
review, see ref. 3). The subsequent discovery of a
prototypic transcription factor that is expressed in Treg
cells, FoxP3, was a key advance not only in identifying
Treg cells, but also in understanding their function.
FoxP3 shapes the pattern of gene expression in Treg
cells, and deficiency of this protein in mice or humans
leads to life-threatening autoimmunity (for review, see
ref. 3). Nevertheless, FoxP3 expression is not always
an accurate indicator that a cell is a Treg cell, as FoxP3
can be briefly expressed during the activation of other
T cells and Treg cells can occasionally lose FoxP3
expression, at least transiently, while maintaining Treg
cell function (4).
Cells of the immune system can typically be
subdivided into two or more subsets, and Treg cells are
no exception—they can be subclassified as either natural
Treg (nTreg) cells or induced Treg (iTreg) cells. Natural
Treg cells arise in the thymus and exist in the mature
T cell population prior to stimulation by encounter with
antigen. Induced Treg cells arise, on the other hand, as
a result of antigenic stimulation in the mature immune
system. Both types of Treg cells express CD25 and can
be expanded by IL-2. A recent report suggests that
nTreg cells and iTreg cells may have unique, distinct,
and nonredundant functional roles in the immune re-
sponse (5). A further level of complexity has been
created by the identification of an additional subset of
iTreg cells, termed iTr35 cells, that secrete IL-35. IL-35
not only mediates some of the regulatory effects of these
cells, but also induces non-Treg cells to differentiate into
iTr35 cells (6).
David A. Fox, MD: University of Michigan Health System,
Ann Arbor.
Address correspondence to David A. Fox, MD, University of
Michigan Health System, Room 3918 Taubman Center, 1500 East
Medical Center Drive, Ann Arbor, MI 48109-0358. E-mail:
dfox@umich.edu.
Submitted for publication March 23, 2012; accepted in revised
form April 17, 2012.
2426
Treg cells carry out their regulatory functions
both by secretion of cytokines, especially IL-10, and by
direct cell–cell contact, in which CTLA-4 on the Treg
cell surface is an important participant. Targets of Treg
cells that are relevant to RA include other T cells,
B cells, dendritic cells, and even osteoclasts (7). Direct
Treg cell interactions with effector T cells can lead to the
suppression of effector T cell proliferation and/or sup-
pression of cytokine production. The complexity of Treg
cell interactions with the entire immune system, includ-
ing their ability to recruit other cells (especially dendritic
cells) to function as secondary or surrogate mediators of
cascades of immune regulation, means that assessment
of Treg cell function requires multiple assays with di-
verse end points. Simple enumeration of these cells is
not sufficient, and is ideally supplemented by a panel of
functional studies.
Treg cells in RA
Treg cells are present in RA, and are not numer-
ically deficient, either systemically or in inflamed syno-
vium. However, they do not appear to function normally,
and in some studies have failed to suppress cytokine
production by effector T cells while still suppressing T
cell proliferation (for review, see ref. 3). Multiple mech-
anisms may interfere with Treg cells in RA. The obser-
vation that tumor necrosis factor (TNF) can impair Treg
cell function has been supplemented by the demonstra-
tion that anti-TNF treatment of RA restores defective
Treg cell function to normal levels (8). Other cytokines,
such as IL-6, can also interfere with Treg cell differen-
tiation and function, and it is plausible that the anti–
IL-6R antibody tocilizumab also corrects defective Treg
cell activity as one of its therapeutic mechanisms in RA.
Beneficial effects of adoptive transfer of CD4CD25
T cells have been seen in animal models of RA, but a
greater understanding of such an approach is needed
before considering its use in human autoimmune dis-
eases.
Consideration of the possible role of Th17 cells in
RA prompts at least two reasons for concern that Treg
cell infusions could actually make RA worse. (Th17 cells,
which secrete IL-17 and were first recognized in 2005
[9,10], have been implicated as important in RA and
many other inflammatory immune conditions.) The first
concern arises from the complex regulatory relation-
ships that exist between the effector T cell subsets. The
major cytokine products of Th1 cells (interferon-) and
Th2 cells (IL-4) are potent suppressors of the develop-
ment and function of Th17 cells, both in normal immune
responses and in autoimmune arthritis models. Th1 and
Th2 cell proliferation and cytokine secretion are, how-
ever, suppressed by Treg cells, while direct suppression
of Th17 cells by Treg cells has been more difficult to
document. Thus, a potential scenario is that Treg cell
infusions, by suppressing Th1 and Th2 populations,
would remove restraints on Th17 cells and make Th17-
related diseases worse.
A second concern arises from the recently recog-
nized plasticity of CD4 T cell subsets, which allows
interconversion of differentiated subsets depending on
the in vitro or in vivo cytokine milieu. The developmen-
tal pathway of Treg cells requires transforming growth
factor  (TGF), while Th17 cell differentiation (in
mice) requires TGF  IL-6. The close relationship
between these pathways raises the possibility that in an
IL-6–rich environment infused Treg cells could actually
change into Th17 cells, while the development of new
Treg cells would be suppressed. Moreover, a peptide
containing critical residues of the RA-associated major
histocompatibility complex allele that is termed the
shared epitope, or a tetrameric form of the shared
epitope, can cause dendritic cells to suppress Treg cell
development and favor Th17 cell differentiation (11).
Induced Treg cells to the rescue
In this context, the report by Kong et al makes
several important points. This group compared nTreg
cells and iTreg cells in the treatment of established CIA.
The nTreg cells were expanded from the mouse thymus
by culture in medium that contained a type II collagen
peptide and IL-2. The iTreg cells were generated from
mouse spleen cells by culture with collagen peptide,
IL-2, and TGF. In the presence of IL-6, only the iTreg
cells, which did not express IL-6R or the associated
signaling molecule STAT-3, were able to sustain the
ability to suppress effector T cell proliferation and
cytokine production in vitro, and, importantly, they
suppressed the development and function of Th17 cells.
While either type of Treg cell could suppress CIA when
injected into mice at the time of initial immunization
with type II collagen, only the iTreg cells were able to
Table 1. Cells that regulate T cell responses
Treg cells (a subset of CD4 T cells)
Dendritic cells
Natural killer T cells
Breg cells
CD8 T cells
Effector Th cell subsets (e.g., Th1, Th2)
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attenuate CIA when the cells were administered 2 weeks
after collagen immunization, which is 1–2 weeks before
arthritis develops in this model. Even after the appear-
ance of clinical arthritis, iTreg cells, but not nTreg cells,
suppressed further progression of disease. By labeling
the infused Treg cells with a fluorescent dye, Kong et al
followed their fate in vivo after injection of these cells
into mice. Some of the nTreg cells died in the mice,
while many lost expression of FoxP3 and converted to
Th17 cells. In contrast, the iTreg cells survived, retained
expression of FoxP3, and continued to function in the
mice with CIA despite the in vivo abundance of proin-
flammatory cytokines. The iTreg cells even led to an
accumulation of endogenous Treg cells in the lymph
nodes in place of Th17 cells, possibly by conversion of
Th17 cells to Treg cells.
This demonstration of a potent effect on a Th17-
driven autoimmune disease in vivo is an important step
forward in demonstrating the encouraging therapeutic
potential of iTreg cells. Whether the iTreg cells act
directly on Th17 cells in vivo in CIA or through inter-
mediates such as dendritic cells is presently unclear, and
will be an interesting issue for further experimentation.
Also unknown is whether late in disease Th17 cells can
become resistant to regulation by iTreg cells, analogous
to their acquisition of resistance to IL-4 (12,13). The
ultimate duration of the in vivo effects of iTreg cells
remains to be clarified.
Nevertheless, the data reported by Kong et al
provide impetus to the concept of enhancing Treg cell
function as a strategy to treat human disease. Enhance-
ment of Treg cell function might ultimately be accom-
plished by approaches that are simpler, safer, and less
costly than infusion of in vitro–expanded iTreg cells.
Diet can even influence the number of circulating Treg
cells. In NZB  NZW mice, which are used as a model
of systemic lupus erythematosus, caloric restriction (a
maneuver known to retard the progression of lupus in
these animals) lowers leptin levels and concurrently
increases the number of Treg cells, an effect that is
reversed by leptin replacement (14). The diverse nature
of the factors that influence Treg cell number and
function suggests that in future clinical trials of a wide
variety of treatments for autoimmune diseases, Treg cell
assays should be considered as worthwhile mechanistic
studies. Such studies will lead to a deeper understanding
of how these cells behave in human rheumatic diseases
and in response to immunomodulatory therapies. The
exciting goal of restoring defective immune regulation
rather than resorting to immunosuppression as the
primary approach to treating RA and other conditions
will then be closer to reality.
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